Dr. Alicia K. Morgans

Dr. Alicia K. Morgans

Sep 3, 2025

Director of Adult Survivorship, Associate Professor of Medicine

Director of Adult Survivorship, Associate Professor of Medicine

Dana-Farber Cancer Institute, Harvard Medical School

Alicia Morgans, MD, MPH, is a Genitourinary Medical Oncologist, Director of the Adult Survivorship Program at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School. A clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. 

Dr. Morgans received her MD degree from the University of Pennsylvania School of Medicine in 2006 and her Master of Public Health (MPH) degree from Vanderbilt University School of Medicine in 2015. 

Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. Her work has been funded by grants from the National Comprehensive Cancer Network, the Prostate Cancer Foundation, and the Department of Defense. She leads multiple therapeutic and quality-of-life focused clinical trials for prostate cancer patients. 

She is a member of the advanced and localized prostate cancer treatment guidelines committee of the American Urologic Association and a member of the cardio-oncology committee of the American Heart Association.  

Go To Session:

Dr. Artie Shelton

Dr. Artie Shelton

Sep 3, 2024

Prostate Cancer Survivor and PHEN Ambassador

Prostate Cancer Survivor and PHEN Ambassador

Colonel (ret) US Army Veteran, President / CEO of Shelton Professional Services

Artie L. Shelton, MD, Colonel (ret) U.S Army veteran, is President CEO of Shelton Professional Services. Dr. Shelton is a committed PHEN advocate and serves as PHEN’s Regional Coordinator for the Washington, D.C area. He is a 20-year prostate cancer survivor/warrior and advocate for the Prostate Health Education Network (PHEN). Dr. Shelton was appointed by Governor O’Malley to serve a six-year term as a member of the Maryland Council on Cancer Control and co-chaired writing the prostate chapter for the Maryland Comprehensive Cancer Control Plan Executive Summary. Dr. Shelton has served on the Department of Defense (DoD) Congressional Directed Medical Research Program (CDMRP) as a consumer reviewer/advocate and on the consumer work group.

Dr. Shelton states that during his person venture, with prostate cancer, he became aware of the magnitude of this disease that is impacting all men, but especially on African American men.

All health organizations must take PHEN’s example in their efforts to combat this disease and potentially cure it if diagnosed early. Faith-based and other organizations need to take advantage of their leadership roles and positions in society to raise public awareness in the fight against prostate cancer.

Go To Session:

Dr. Richard Lee

Dr. Richard Lee

Aug 17, 2023

Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers, Assistant Physician

Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers, Assistant Physician

Mass General Cancer Center

After completing a bachelor’s and a master’s degree at Harvard, Richard Lee, MD, PhD, then completed his medical school (M.D.) and graduate school (Ph.D.) training at the Albert Einstein College of Medicine in the Bronx, New York. He came to Mass General Hospital (MGH) for internal medicine residency training and then completed a medical oncology fellowship through the Dana-Farber Cancer Institute/MGH joint program. During that time, he performed basic science research at the Whitehead Institute of MIT.

Go To Session:

Dr. Keith Crawford

Dr. Keith Crawford

Aug 3, 2023

Director of Clinical Trials and Patient Education

Director of Clinical Trials and Patient Education

PHEN

Dr. Keith Crawford joined PHEN in 2019.  As Director of Clinical Trials and Patient Education, he is responsible for implementing programs in these areas as well as working with patients and PHEN partners.

Dr. Crawford has more than 20 years of experience in the Life Sciences and completed his graduate and post-graduate training at Harvard Medical School where he developed competencies in the area of genomics, proteomics, immunology, microbiology, infectious diseases, and regenerative medicine.

During his post-doctoral training, Keith was selected by the Robert Wood Johnson Foundation as a Harold Amos Fellow. His work in the field of immunology caught the eye of the Department of Defense where he received funding to develop antidotes for chemical and biological weapons exposure as well as create a high throughput platform for the detection of biological weapons and emerging infectious agents.

After completing this directive, Dr. Crawford became the Director of the Center for Molecular Orthopedics at Brigham and Women’s Hospital. He was responsible for leading research efforts at the center, which gave rise to the discovery of a novel population of early lineage adult stem cells.  Dr. Crawford and his colleagues were responsible for the preclinical studies, which laid the foundation for a spinal fusion therapeutic. 

Dr. Crawford is a graduate of Prairie View University, the University of Texas Medical School in Houston (Medical Doctorate), and Harvard University (Doctor Philosophy) where he studied cell biology and immunology.

Go To Session:

Mr. Thomas A. Farrington

Mr. Thomas A. Farrington

Aug 2, 2023

President and Founder

President and Founder

PHEN

Thomas Farrington founded the Prostate Health Education Network (PHEN) in 2003 after receiving treatment for prostate cancer in 2000 and publishing his first book Battling The Killer Within in 2001. Under Mr. Farrington’s leadership, PHEN is recognized as the leading prostate cancer education and advocacy organization with national programs and initiatives focused on the needs of African Americans.

A key foundation for PHEN’s success is its national network of prostate cancer survivors and their loved ones who support the organization’s efforts within their communities. PHEN partners with hundreds of churches across the nation to bring education and awareness programs into their communities and recruit local prostate cancer medical specialists as educators for these events.

PHEN also makes extensive use of online programming to reach and support individual educational needs. Mr. Farrington’s background is in Information Technology.  Farrington currently serves as a member of the National Comprehensive Cancer Network’s (NCCN) Prostate Cancer Treatment Guidelines Panel and the NCCN Prostate Cancer Early Detection Guidelines Panel. He serves as a trustee of the Dana-Farber Cancer Institute and as an advisor to a number of other healthcare organizations and programs. Mr. Farrington received a B.S. in Electrical Engineering from North Carolina Agricultural and Technical State University in 1966.

Go To Session:

David Vasir, PhD

David Vasir, PhD

Aug 31, 2022

Senior Research Analyst

Senior Research Analyst

PHEN

David Vasir PhD, Senior Research Analyst, PHEN, earned his Bachelor of Science degree at University of St. Andrews, Fife, Scotland, U.K IN 1981 and his Master of Science Degree at University of Wales College of medicine Wales, UK in 1985. He then went on to earn his Doctor of Philosophy at Jesus College & Oxford University Medical School, U.K in 1991. Dr. Vasir has been an investigator on several cancer vaccine programs where he designed and implemented number of immunological based assays to monitor the pre- and post-vaccination immunological status of patients with breast, renal ovarian carcinomas, and patients with multiple myeloma in cancer vaccine clinical trials. Majority of these analysis pertained to a detailed pre- and post-vaccination analysis of the immune status as determined by Th1 and Th2 immune responses, levels and functions of regulatory T cells as determined by surface markers, and FOXP3 expression and specific and non-specific immunological analysis. In addition, Dr. Vasir has extensively studied ex-vivo the immunobiology of antigen induced regulatory T cells from their phenotypic characteristics using six color flow cytometry analysis, to their invitro functional properties, their interaction with antigen presenting cells, detailed Th1 and Th2 cytokine profiles of segregated populations of regulatory T cells using multiplex arrays, use of various strategies to reverse the suppressive properties of these cells. Dr. Vasir also investigated the identification of specific microRNAs and kinases in six color sorted regulatory T cells isolated from the ascites of patients with advanced ovarian cancer, identification and targeting of cancer stem cells using small molecules, isolation, and characterization of stem cells for regenerative medicine.